TY - JOUR
T1 - Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia
T2 - Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
AU - Nørgaard, Caroline Holm
AU - Friedrich, Sarah
AU - Hansen, Charlotte Thim
AU - Gerds, Thomas
AU - Ballard, Clive
AU - Møller, Daniel Vega
AU - Knudsen, Lotte Bjerre
AU - Kvist, Kajsa
AU - Zinman, Bernard
AU - Holm, Ellen
AU - Torp-Pedersen, Christian
AU - Mørch, Lina Steinrud
N1 - © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
AB - Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85131062735&partnerID=8YFLogxK
U2 - 10.1002/trc2.12268
DO - 10.1002/trc2.12268
M3 - Journal article
C2 - 35229024
SN - 2352-8737
VL - 8
SP - e12268
JO - Alzheimer's & Dementia: Translational Research & Clinical Interventions
JF - Alzheimer's & Dementia: Translational Research & Clinical Interventions
IS - 1
M1 - e12268
ER -